caki-2 cell line Search Results


caki-2 cell line  (Interlab Inc)
90
Interlab Inc caki-2 cell line
Caki 2 Cell Line, supplied by Interlab Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/caki-2 cell line/product/Interlab Inc
Average 90 stars, based on 1 article reviews
caki-2 cell line - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
caki2 cell line  (Merck & Co)
90
Merck & Co caki2 cell line
Caki2 Cell Line, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/caki2 cell line/product/Merck & Co
Average 90 stars, based on 1 article reviews
caki2 cell line - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
sunitinib-resistant caki-2 cell line  (LC Laboratories)
90
LC Laboratories sunitinib-resistant caki-2 cell line
Patient characteristics.
Sunitinib Resistant Caki 2 Cell Line, supplied by LC Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sunitinib-resistant caki-2 cell line/product/LC Laboratories
Average 90 stars, based on 1 article reviews
sunitinib-resistant caki-2 cell line - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Patient characteristics.

Journal: PLoS ONE

Article Title: Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma

doi: 10.1371/journal.pone.0086263

Figure Lengend Snippet: Patient characteristics.

Article Snippet: A sunitinib-resistant Caki-2 cell line (SRCaki-2) was generated by continuous exposure for four months to gradually increasing doses of sunitinib: From 8 μM to 14 μM (Sutent, LC laboratories).

Techniques: Biomarker Discovery

, (sunitinib sensitive, n = 14 and sunitinib resistant, n = 6). MiR-942, miR-628-5p, miR-133a and miR-484 were overexpressed in sunitinib resistant patients. MiR-942 significantly discriminated between both patients groups. MiRNA levels are represented as 2 −ΔCt mean ± SEM. MiRNA expression was normalized against RNU6B. R = responders. NR = non responders.

Journal: PLoS ONE

Article Title: Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma

doi: 10.1371/journal.pone.0086263

Figure Lengend Snippet: , (sunitinib sensitive, n = 14 and sunitinib resistant, n = 6). MiR-942, miR-628-5p, miR-133a and miR-484 were overexpressed in sunitinib resistant patients. MiR-942 significantly discriminated between both patients groups. MiRNA levels are represented as 2 −ΔCt mean ± SEM. MiRNA expression was normalized against RNU6B. R = responders. NR = non responders.

Article Snippet: A sunitinib-resistant Caki-2 cell line (SRCaki-2) was generated by continuous exposure for four months to gradually increasing doses of sunitinib: From 8 μM to 14 μM (Sutent, LC laboratories).

Techniques: Expressing

TTP and OS were significantly reduced in MRCC patients treated with sunitinib that had ( A ) miR-942 expression over the mean; ( B ) miR-628-5p levels over the mean; ( C ) miR-133a levels over p75; ( D ) and miR-484 expression over the mean.

Journal: PLoS ONE

Article Title: Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma

doi: 10.1371/journal.pone.0086263

Figure Lengend Snippet: TTP and OS were significantly reduced in MRCC patients treated with sunitinib that had ( A ) miR-942 expression over the mean; ( B ) miR-628-5p levels over the mean; ( C ) miR-133a levels over p75; ( D ) and miR-484 expression over the mean.

Article Snippet: A sunitinib-resistant Caki-2 cell line (SRCaki-2) was generated by continuous exposure for four months to gradually increasing doses of sunitinib: From 8 μM to 14 μM (Sutent, LC laboratories).

Techniques: Expressing

( A ) Migration of HBMEC was significantly increased after co-culture with miR-942/Caki-2 (*: p<0.05), as compared with co-culture with miR-Neg/Caki-2 cells. ( B ) HBMEC became less sensitive to sunitinib activity after co-culture with miR-942/Caki-2 (LD 50 >35 µM) in comparison to HBMEC co-cultured with miR-Neg/Caki-2 cells (LD 50 13.5 µM). ( C ) Phosphorylation of VEGFR2 and p44/42 MAPK (Erk1/2) proteins was increased in HBMEC co-cultured with miR-942/Caki-2, as compared to the co-culture with miR-Neg/Caki-2 cells.

Journal: PLoS ONE

Article Title: Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma

doi: 10.1371/journal.pone.0086263

Figure Lengend Snippet: ( A ) Migration of HBMEC was significantly increased after co-culture with miR-942/Caki-2 (*: p<0.05), as compared with co-culture with miR-Neg/Caki-2 cells. ( B ) HBMEC became less sensitive to sunitinib activity after co-culture with miR-942/Caki-2 (LD 50 >35 µM) in comparison to HBMEC co-cultured with miR-Neg/Caki-2 cells (LD 50 13.5 µM). ( C ) Phosphorylation of VEGFR2 and p44/42 MAPK (Erk1/2) proteins was increased in HBMEC co-cultured with miR-942/Caki-2, as compared to the co-culture with miR-Neg/Caki-2 cells.

Article Snippet: A sunitinib-resistant Caki-2 cell line (SRCaki-2) was generated by continuous exposure for four months to gradually increasing doses of sunitinib: From 8 μM to 14 μM (Sutent, LC laboratories).

Techniques: Migration, Co-Culture Assay, Activity Assay, Comparison, Cell Culture, Phospho-proteomics